5.00517

SKP2 E3 Ligase Inhibitor II, SMIP004

• 別名: SKP2 E3 Ligase Inhibitor II, SMIP004, CRL1 ^SKP2 Inhibitor II, p21/Cip1/CKI/Waf1 Activator II, p27/Kip1 Activator II, S-phase Kinase-associated Protein 2 Inhibitor II, SCF ^SKP2 Inhibitor II, Small Molecule Inhibitor of p27 Depletion 004, N-(4-Butyl-2-methylphenyl)acetami, CRL1^SKP2 Inhibitor II, p21/Cip1/CKI/Waf1 Activator II, p27/Kip1 Activator II, S-phase Kinase-associated Protein 2 Inhibitor II, SCF^SKP2 Inhibitor II, Small Molecule Inhibitor of p27 Depletion 004, N-(4-Butyl-2-methylphenyl)acetamide
• 実験式（ヒル表記法）: C₁₃H₁₉NO
• CAS番号: 143360-00-3
• 分子量: 205.30
• MDL番号: MFCD00277686
• UNSPSCコード: 12352200
• NACRES: NA.77

特性

• アッセイ: ≥99% (HPLC)
• 品質水準: 100
• フォーム: solid
• メーカー／製品名: Calbiochem^®
• 保管条件: OK to freeze; protect from light
• 色: white
• 溶解性: DMSO: 100 mg/mL
• 保管温度: 2-8°C
• SMILES記法: N(c1c(cc(cc1)CCCC)C)C(=O)C
• InChI: 1S/C13H19NO/c1-4-5-6-12-7-8-13(10(2)9-12)14-11(3)15/h7-9H,4-6H2,1-3H3,(H,14,15)
• InChI Key: ZFVMECVBUGMWIX-UHFFFAOYSA-N

詳細

詳細

A cell-permeable phenylacetamide compound that is shown to upregulate p21^Cip1/Waf1 and/or p27^Kip1 in prostate cancer LNCaP, PC3, DU145, but not HeLa, cultures (40 µM for 24 h) with a concomitant downregulation of the F-box E3 ubiquitin ligase Skp2 and a delayed G1-to-S cell cycle transition, displaying no apparent effect toward cell cycle progression or p21 and p27 levels in non-cancer human fibroblast IMR90. SMIP004 antiproliferative activity against LNCaP, PC3, DU145 soft agar colony formation is mainly cytostatic with cytotoxicity observed only in LNCaP cultures at high concentrations (IC₅₀ = 40 µM in 72 h), but not PC3 or DU145 even at concentrations as high as 80 µM and for up to 96 h.

Please note that the molecular weight for this compound is batch-specific due to variable water content. Please refer to the vial label or the certificate of analysis for the batch-specific molecular weight. The molecular weight provided represents the baseline molecular weight without water.

A cell-permeable phenylacetamide compound that is shown to upregulate p21^Cip1/Waf1 and/or p27^Kip1 in prostate cancer LNCaP, PC3, DU145, but not HeLa, cultures (Fold of control p21/27 levels = 2.7/2.1, 1.7/1,1, 1.7/1.3, and 1.1/1.1, respectively; 24 h 40 µM treatment) with a concomitant downregulation of the F-box E3 ubiquitin ligase Skp2 and a delayed G1-to-S cell cycle transition (G1 population with/ without 24 h 40 µM drug treatment = 81.7%/70.8%, 58.5%/42.2%, 75.7%/40.5%, respectively; S population with/ without 24 h 40 µM drug treatment = 7.9%/18.0%, 14.3%/26.7%, 14.1%/44.0%, respectively), displaying no apparent effect toward cell cycle progression or p21 and p27 levels in non-cancer human fibroblast IMR90. SMIP004 antiproliferative activity against LNCaP, PC3, DU145 soft agar colony formation is mainly cytostatic in nature and SMIP004 cytotoxic effect is observed only in LNCaP cultures at high concentrations (IC₅₀ = 40 and 2.4 µM, respectively, with 72 h or 96 h treatment), but not PC3 or DU145 even at concentrations as high as 80 µM and for up to 96 h.

生物化学的／生理学的作用

Cell permeable: yes

Reversible: yes

包装

Packaged under inert gas

警告

Toxicity: Standard Handling (A)

再構成

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

その他情報

Rico-Bautista, E., and Wolf, D.A. 2012. Chem. Biol.19, 1497.
Rico-Bautista, E., et al. 2010. BMC Biol.8, 153.

法的情報

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

安全性情報

• 保管分類コード: 11 - Combustible Solids
• WGK: WGK 2